Last reviewed · How we verify
IPI-549
PI3K/mTOR inhibitor
PI3K/mTOR inhibitor Used for Solid tumors, Non-small cell lung cancer.
At a glance
| Generic name | IPI-549 |
|---|---|
| Also known as | Eganelisib |
| Sponsor | Arcus Biosciences, Inc. |
| Drug class | PI3K/mTOR inhibitor |
| Target | PI3K/mTOR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
IPI-549 is a potent and selective inhibitor of PI3K/mTOR, which plays a critical role in cell growth and survival. By inhibiting this pathway, IPI-549 has shown promise in treating various cancers.
Approved indications
- Solid tumors
- Non-small cell lung cancer
Common side effects
- Fatigue
- Diarrhea
- Nausea
Key clinical trials
- Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia (PHASE1)
- IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma (PHASE2)
- A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (PHASE1)
- Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (PHASE2)
- Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) (PHASE2)
- A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |